Press Room

Drug Delivery to the Lungs - DDL25

Start
Wednesday, December 10, 2014 - 00:00
End
Friday, December 12, 2014 - 00:00
Location: Edinburgh, Scotland, UK
Booth Number: 36 A

DDL25 will be held from Wednesday 10th December until Friday 12th December 2014 at the Edinburgh International Conference Centre, Edinburgh, Scotland, UK. Hovione will be present with a booth (36 A) and a set of posters.

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at DDL.

contact us button | Hovione

 

HOVIONE POSTERS

Respiratory targeting: Drug-alone Formulations enabled by Particle Engineering
Nick Barker, Gaauri Naik, Sofia Silva & Eunice Costa

Screening and Optimization of Formulation and Process Parameters for the Manufacture of Inhalable Composite Particles by Spray-drying
Cláudia Moura, João Vicente, Maria Palha, Filipe Neves, Ana Aguiar-Ricardo & Eunice Costa

On the performance of coarse and fine lactose blends for DPIs: Part A – rheology behavior
Filipa M. Maia, Maria Palha, Isabel S. Lopes & Filipe Neves

On the performance of coarse and fine lactose blends for DPIs: Part B - capsule filling and device performance
Maria Palha, Filipa M. Maia, João V. Fernandes & Filipe Neves

The Influence of the Formulation and Delivery Approach on the Aerodynamic Performance of Salmeterol Xinafoate
Cláudia Moura, Sofia Silva, Filipe Neves, Ana Aguiar-Ricardo & Eunice Costa

 

DOWNLOAD POSTERS
The posters will be available after the conference and by pre-registration only. To assure that you get your copy, complete the pre-registration below.

pre-register button | Hovione

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025